4/A: Processa CDO Amends Ownership Filing

Processa Pharmaceuticals' Chief Development Officer, Sian Bigora, filed an amended Form 4 to retract a previously filed beneficial ownership statement.

Summary

• Sian Bigora, Chief Development Officer of Processa Pharmaceuticals, Inc. (PCSA), filed an amended Form 4/A.
• The amendment retracts a prior Form 4 that was filed in error.
• Following this correction, Ms. Bigora directly beneficially owns 33,626 shares of Common Stock.
• An additional 6,668 shares of Common Stock are indirectly beneficially owned by CorLyst, LLC.

Sentiment

Score: 5

Explanation: The filing is a neutral administrative correction, retracting a previously filed Form 4 due to an error. It does not indicate positive or negative operational or financial performance.

Positives

• The company and its officer are demonstrating transparency and compliance by promptly correcting an erroneous SEC filing.
• The correction ensures an accurate public record of insider beneficial ownership.

Negatives

• An initial administrative error occurred in the prior Form 4 filing, necessitating this amendment.

Risks

• The potential for administrative errors in SEC filings, which could lead to temporary inaccuracies in public disclosures.

Management Comments

• Amendment filed to retract the prior Form 4, which was filed in error.

Industry Context

This filing is a routine compliance update for an individual insider's beneficial ownership and does not reflect broader industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: Provides accurate information regarding insider ownership, enhancing transparency.
• Regulatory Authorities: Ensures compliance with SEC reporting requirements.

Key Dates

Keywords

Processa Pharmaceuticals, PCSA, Sian Bigora, Form 4/A, beneficial ownership, insider ownership, SEC filing, Chief Development Officer, corporate compliance